Cencora COR

Cencora, Inc. has faced financial turbulence following its acquisition of OneOncology for approximately $4.6 billion, amid rising operational expenses and significant debt. With total revenue rising by only 5.5% yet operating expenses surging nearly 25%, the company reported a revenue miss for fiscal Q2 2026, leading to a stock decline of 16.4%. In response, Cencora has adjusted its earnings outlook and initiated a $2 billion share buyback program. Recent deals, including a merger with MWI Animal Health and refinancing measures, aim to stabilize its financial footing, though ongoing regulatory uncertainties and market sentiment remain a concern.